Results 31 to 40 of about 4,861,637 (146)

Re-irradiation for oligoprogression under Nivolumab in recurrent head and neck squamous cell carcinoma: A case report

Clinical and Translational Radiation Oncology, 2020
Immune checkpoint inhibitors (ICIs) represent a recently introduced class of agents active in head and neck squamous cell carcinoma (HNSCC). For a subgroup of patients with recurrent or metastatic disease, long-term benefit can be achieved: maintaining a
Pierluigi Bonomo, Sara Lucidi, Isacco Desideri, Vieri Scotti, Marta Casati, Annarita Palomba, Cinzia Ciabatti, Pietro Garlatti, Daniela Massi, Oreste Gallo, Lorenzo Livi   +10 more
doaj   +1 more source

Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY. [PDF]

, 2010
The unparalleled collection of clinical data and biomaterials within the EHDN's REGISTRY can expedite the search for disease modifiers (genetic and environmental) of age at onset and disease progression that could be harnessed for the development of ...
Handley, Olivia J, Landwehrmeyer, G Bernhard, Aileen K Ho, Bisson, Jonathan Ian, Schwenke C, David Craufurd, Dunnett, Stephen B., Handley, Olivia, Investigators of the European Huntington's Disease Network, The, DI MARIA, EMILIO, Craufurd D, Dunnett, SB, Carsten Schwenke, the investigators of the European Huntington's Disease Network, Craufurd, David, Edward Wild, Landwehrmeyer, GB, Busse, Monica, Rosser, Anne Elizabeth, Olivia J Handley, Romano Silvia., Tabrizi SJ, Ho, Aileen K., Wild, E, Landwehrmeyer GB, Craufurd, D, Tabrizi, SJ, Tabrizi, Sarah J., Handley, OJ, Rickards, Hugh, Dunnett, Stephen, Ho, Aileen K, Orth, Michael, Ho, AK, Wild, Edward, Stephen B. Dunnett, Sarah J Tabrizi, Wild, EJ, Landwehrmeyer, G. Bernhard, Naji, Jenny, Landwehrmeyer, G. Bernhard, Wild E, Investigators of the European Huntington's Disease Network, Handley, Olivia J., Orth, M, Ellison-Rose, Lynda, Tabrizi, Sarah J, Price, Kathleen, Ho AK, ABBRUZZESE, GIOVANNI, Schwenke, C, Ho, A, Orth M, Handley OJ, Schwenke, Carsten, Dunnett SB, Dunnett, Stephen B, Michael Orth, G. Bernhard Landwehrmeyer   +59 more
core   +1 more source

Stereotactic ablative radiotherapy for acquired resistance to EGFR therapy in metastatic non-small cell lung cancer

Frontiers in Oncology, 2023
The advent of targeted therapy has transformed the treatment paradigm and survival of patients with metastatic non-small cell lung cancer (NSCLC) with driver mutations.
Rodolfo Chicas-Sett, Juan Castilla Martinez, Abrahan Hernández Blanquisett, Juan Zafra, Juan Zafra, Juan Zafra, Jorge Pastor-Peidro   +6 more
doaj   +1 more source

Treatment of Metastatic Her2Neu+ Breast Cancer with Oligoprogressive Disease [PDF]

Background Information: In treating metastatic Her2Neu+ breast cancer, trastuzumab-based chemotherapy regimens typically result in fairly durable tumor control.
Ayub, Jinan, Newton, Erin, Kenyon, Taylor, Ramchandani, Muskaan, Pelton, Sarah   +4 more
core   +3 more sources

Metastasis-Directed Surgery for Solitary Pulmonary Metastasis After Pembrolizumab in Urothelial Carcinoma: A Case Report. [PDF]

IJU Case Rep
ABSTRACT Introduction The role of metastasis‐directed therapy in urothelial carcinoma remains uncertain, particularly in the immune checkpoint inhibitor era. We report a case of solitary pulmonary metastasis that developed after a favorable response to pembrolizumab and was managed with metastasectomy.
Takemura K, Tanaka M, Hamada Y, Karasaki T, Sakaguchi K, Uruga H, Urakami S, Fujimori S, Uchino K.   +8 more
europepmc   +2 more sources

Role of Radiotherapy in the Era of Novel Immune-Based Treatment Strategies for Multiple Myeloma. [PDF]

Hematol Oncol
ABSTRACT Radiotherapy (RT) constitutes an important treatment modality in multiple myeloma (MM), traditionally used for the management of symptomatic osteolytic and extramedullary lesions. Objectives of RT are symptom alleviation and prevention of complications such as neurological deficits and pathological fractures.
Schlusemann T, Shumilov E, Reinartz G, Steike DR, Lohmann S, Gravemeyer S, Stelljes M, Lenz G, Eich HT, Oertel M.   +9 more
europepmc   +2 more sources

Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer

, 2022
Introduction: Some patients with cancer may present with progressive or persistent disease at a limited number of sites following a period of treatment response.
박은정, 장지석, 금웅섭, 변화경, 안중배, 신상준, 김한상, 김미선, 양고운, 이정심, 범승훈   +10 more
core   +1 more source

Dose-escalated radiotherapy with simultaneous integrated boost for bone metastases in selected patients with assumed favourable prognosis

Radiology and Oncology, 2022
Stereotactic body radiotherapy (SBRT) concepts for dose escalation are increasingly used for bone metastases in patients with oligometastatic or oligoprogressive disease.
Potkrajcic Vlatko, Mueller Arndt-Christian, Frey Bettina, Gani Cihan, Zips Daniel, Hoffmann Ruediger, Frantz Sandra, Warm Verena, Paulsen Frank, Eckert Franziska   +9 more
doaj   +1 more source

Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study [PDF]

, 2019
PURPOSE: Herein, we report the clinical outcomes of a multicenter study evaluating the role of SBRT in a cohort of patients affected by oligoprogressive castration-resistant prostate cancer (CRPC).
Bortolus, Roberto, Bruni, Alessio, Franzese, Ciro, Jereczek-Fossa, Barbara Alicja, Triggiani, Luca, Mazzeo, Ercole, Matrone, Fabio, Buglione, Michela, Francolini, Giulio, Bonù, Marco Lorenzo, Trippa, Fabio, Paiar, Fabiola, Borghetti, Paolo, Detti, Beatrice, Fanetti, Giuseppe, Pasqualetti, Francesco, Alongi, Filippo, Ingrosso, Gianluca, Mazzola, Rosario, Lancia, Andrea, Ost, Piet, Maranzano, Ernesto, Scorsetti, Marta, Magrini, Stefano Maria, Magli, Alessandro   +24 more
core   +2 more sources

Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial

BMC Cancer, 2020
Background Patients diagnosed with metastatic castration-refractory prostate cancer (mCRPC) rely on a limited number of therapeutic agents resulting in a median survival of 2–3 years. A subgroup of those patients with mCRPC presents with oligoprogressive
Charlien Berghen, Steven Joniau, Kato Rans, Gaëtan Devos, Kenneth Poels, Koen Slabbaert, Herlinde Dumez, Maarten Albersen, Karolien Goffin, Karin Haustermans, Gert De Meerleer   +10 more
doaj   +1 more source